Wall Street brokerages predict that Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will announce ($0.31) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xeris Pharmaceuticals’ earnings. Xeris Pharmaceuticals posted earnings per share of ($0.89) during the same quarter last year, which suggests a positive year-over-year growth rate of 65.2%. The company is scheduled to report its next quarterly earnings report on Thursday, May 6th.

On average, analysts expect that Xeris Pharmaceuticals will report full year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.19) to ($1.00). For the next year, analysts expect that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($0.80) to ($0.69). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last released its earnings results on Monday, March 8th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $7.09 million during the quarter, compared to analyst estimates of $9.19 million. Xeris Pharmaceuticals had a negative net margin of 2,037.97% and a negative return on equity of 435.27%.

Separately, Zacks Investment Research raised Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 13th.

Shares of NASDAQ XERS traded down $0.11 during mid-day trading on Tuesday, reaching $3.59. 2,457,153 shares of the company’s stock were exchanged, compared to its average volume of 2,479,589. The firm has a market capitalization of $214.56 million, a price-to-earnings ratio of -0.90 and a beta of 2.22. The company has a current ratio of 6.86, a quick ratio of 6.65 and a debt-to-equity ratio of 4.49. The business has a fifty day simple moving average of $4.19 and a 200 day simple moving average of $4.99. Xeris Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $7.94.

In related news, insider Steven Prestrelski sold 10,000 shares of Xeris Pharmaceuticals stock in a transaction that occurred on Monday, April 12th. The stock was sold at an average price of $4.07, for a total value of $40,700.00. Following the sale, the insider now owns 496,824 shares of the company’s stock, valued at approximately $2,022,073.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.12% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in XERS. Marshall Wace LLP acquired a new stake in Xeris Pharmaceuticals in the 1st quarter valued at approximately $245,000. Marshall Wace North America L.P. acquired a new stake in Xeris Pharmaceuticals in the 1st quarter valued at approximately $71,000. FMR LLC raised its position in Xeris Pharmaceuticals by 29.9% in the 1st quarter. FMR LLC now owns 2,963,018 shares of the company’s stock valued at $29,749,000 after buying an additional 682,050 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Xeris Pharmaceuticals by 16.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 107,496 shares of the company’s stock valued at $638,000 after buying an additional 14,950 shares during the last quarter. Finally, Miracle Mile Advisors LLC grew its stake in Xeris Pharmaceuticals by 32.1% in the fourth quarter. Miracle Mile Advisors LLC now owns 119,300 shares of the company’s stock valued at $587,000 after purchasing an additional 29,000 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Recommended Story: G-20

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.